10:52:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-26 Årsstämma 2024
2024-05-29 Kvartalsrapport 2024-Q1
2024-03-06 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaEuronext Growth Oslo
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2022-06-28 15:11:08
SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces the publication of data from a randomized control trial
(RTC) evaluating the wound-healing effect of SoftOx's stabilized hypochlorous
acid solution (HOCl) on acute wounds. The results were published in Acta
Dermato-Venereologica, a peer-reviewed journal focused on clinical and
experimental research in dermatology and venerology.

The randomized trial applied a suction blister wound model and randomized 20
healthy volunteers whereby stabilized hypochlorous acid or control (saline)
solutions were assigned. The study's primary objective was to evaluate the wound
healing properties of HOCI, and the secondary objective was microbiological
control, pain levels and safety with stabilized HOCl compared to the control

Wounds were treated and rinsed on days 0, 2 and 4. Wound healing was assessed
blindly, and bacterial growth was evaluated as the number of colony-forming
units cultured from surface swabs.

Stabilized HOCI was found to accelerate early re-epithelialization (wound
healing) significantly on day 4 compared with the control group (p=0.00051) and
was not inferior to the control solution on day 10 (p<0.0001). In addition, the
median bacterial counts in the wounds were significantly lower after treatment
with stabilized HOCI compared with the control group directly after treatment,
which also lasted over time.

Overall, the study demonstrates the immediate and durable antimicrobial action
and beneficial effect of stabilized HOCI on acute wounds and suggests that
hypochlorous acid is a promising antimicrobial wound rinsing agent.

The full title of the publication is: Effect of Stabilized Hypochlorous Acid on
Re-epithelialization and Bacterial Bioburden in Acute Wounds: A Randomized
Controlled Trial in Healthy Volunteers" and can be accessed here:

Co-author and medical director of SoftOx Solutions Glenn Gundersen, commented:
"We are encouraged by these data, which demonstrate the potential of stabilized
hypochlorous acid as a well-tolerated wound irrigation device with significant
antimicrobial properties. We know that the overuse or misuse of antibiotics is
linked to the emergence of antimicrobial resistance, so it is crucial to
identify new and effective treatments to prevent and treat wound infections
without inducing resistant microbes. "

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com